About IGF-DES
N-terminal truncation eliminates IGFBP binding, leaving nearly all circulating IGF-DES unbound and active. Results in substantially higher tissue IGF-1R activation versus native IGF-1 at equivalent doses. Activates PI3K/Akt/mTOR for muscle hypertrophy and satellite cell proliferation.
A truncated form of IGF-1 with the first 3 amino acids removed. Does not bind IGF binding proteins (IGFBPs), resulting in dramatically higher free active concentration at tissue level. Considered highly anabolic with limited systemic safety data in humans.
Research Areas
Regulatory & Evidence
Risk Profile
Higher risk profile in research contexts. Review all contraindications carefully. Not suitable for self-administration without professional oversight.
Regulatory Status
- Availability Status
- Research Only
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Safety Notes
Higher risk profile in research contexts. Professional oversight recommended.
Reported contraindications & considerations
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Where to Find IGF-DES
1 providerOnline Vendors
1 providerFrequently Asked Questions — IGF-DES
A truncated form of IGF-1 with the first 3 amino acids removed. Does not bind IGF binding proteins (IGFBPs), resulting in dramatically higher free active concentration at tissue level.
muscle hypertrophy, localized anabolism, satellite cell activation, tissue growth.
1 provider in the directory currently offers IGF-DES.